(Q44824850)

6 December 2017

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia (English)

1 reference

6 December 2017

1 reference

1 reference

L J Hak

1

1 reference

6 December 2017

M V Relling

2

1 reference

6 December 2017

C Cheng

3

1 reference

6 December 2017

D Pei

4

1 reference

6 December 2017

B Wang

5

1 reference

6 December 2017

J T Sandlund

6

1 reference

6 December 2017

J Rubnitz

7

1 reference

6 December 2017

C-H Pui

8

1 reference

6 December 2017

1 June 2004

1 reference

6 December 2017

1 reference

6 December 2017

18

1 reference

6 December 2017

6

1 reference

6 December 2017

1072-1077

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403351

6 December 2017

0 references

cites work

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Immunological responses to L-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

L-asparaginase and PEG asparaginase--past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Toxicity of E. coli L-asparaginase in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

Acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

L-asparaginase: clinical, biochemical, pharmacological, and immunological studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Comparative pharmacokinetic studies of three asparaginase preparations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403351

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403351

1 reference

Dimensions Publication ID

6 December 2017

0 references

1 reference